gave a case study that employed the use of Statistical Moment Theory: Mean Time to justify the regulatory disintegration test with regulatory authorities. Hans Jürgen Knitter, Bayer/Erweka, Germany, spoke on "Automation in Dissolution." He discussed the pros and cons of automation and described different types of automation that are applied to dissolution testing. Validation of the transfer of a manual method to an automated method was described.
The second day was serial translation in Russian for the remaining three talks that were in English. The first speaker was Igor Shohin (senior lecturer in First MSMU; Head of lab in Chemrar, Russia), who spoke on "Biowaiver Procedures-Practical Aspects." The lecture was devoted to some practical aspects of the biowaiver procedure, solubility and permeability determinations, and comparative dissolution kinetic studies with some examples. Biowaivers are not accepted in Russia by the regulatory authorities, but workshop attendees realized the importance of BCS-based biowaiver procedures. In addition, results of some First MSMU team studies were provided, and a presentation from the pharmacokinetic and dissolution laboratory was shown. Nikoletta Fotaki returned to discuss "From Dissolution to BA/BE Studies." She gave case studies where modeling and appropriate in vivo data led to successful development of IVIVCs. Then Johannes Krämer spoke on "Examination of Level B Correlations with a BCS Class 2 Immediate-Release Formulation." He presented a case study using multisource propafenon film-coated tablets where the use of level B correlation of mean times provided an IVIVC. After lunch, Olga Baula (National Expert in Quality of Medicines, WHO Expert, Ukraine) gave a talk on the regulatory aspects of biowaiver procedures in Ukraine. Baula spoke about the practical use of biowaiver procedures for drug product approvals in Ukraine. Several real cases were described, and the structure of the biowaiver dossier was provided. Then there were three short communications. The first, given by I. G. Smekhova, Asst. Prof., SPCPA, Saint Petersburg, Russia, was "Application of Biowaiver Procedure to Russian Generic Drug Products." She said that to prevent the manufacture of pharmaceutically nonequivalent drugs and to improve the quality of solid oral dosage forms, the use of the dissolution test is necessary for medicines with the same active ingredient. She shared experiences of the application of the dissolution test and biowaiver procedure to the evaluation of generic drugs marketed in Russia and 
